Free Trial
NASDAQ:VRNA

Verona Pharma PLC American Depositary Share Q2 2025 Earnings Report

Verona Pharma PLC American Depositary Share logo
$105.28 -0.12 (-0.11%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$105.26 -0.02 (-0.02%)
As of 08/8/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verona Pharma PLC American Depositary Share EPS Results

Actual EPS
$0.13
Consensus EPS
-$0.01
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Verona Pharma PLC American Depositary Share Revenue Results

Actual Revenue
$103.14 million
Expected Revenue
$90.41 million
Beat/Miss
Beat by +$12.73 million
YoY Revenue Growth
N/A

Verona Pharma PLC American Depositary Share Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Verona Pharma PLC American Depositary Share's Q3 2025 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

Verona Pharma PLC American Depositary Share Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Verona Pharma PLC American Depositary Share Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma PLC American Depositary Share? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma PLC American Depositary Share and other key companies, straight to your email.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

View Verona Pharma PLC American Depositary Share Profile

More Earnings Resources from MarketBeat